Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry.

[1]  M. Humbert,et al.  Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. , 2020, Respiratory medicine.

[2]  Amit J. Shah,et al.  Mortality in US veterans with pulmonary hypertension: a retrospective analysis of survival by subtype and baseline factors , 2019, Pulmonary circulation.

[3]  J. Lumens,et al.  Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update , 2019, European Respiratory Journal.

[4]  M. Humbert,et al.  Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives , 2019, European Respiratory Journal.

[5]  Paul G. Williams,et al.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.

[6]  S. Rosenkranz,et al.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.

[7]  O. Sitbon,et al.  Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  O. Franco,et al.  The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  M. Humbert,et al.  Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. , 2016, The Lancet. Respiratory medicine.

[10]  H. Ghofrani,et al.  Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. , 2016, The Lancet. Respiratory medicine.

[11]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[12]  R. Benza,et al.  Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.

[13]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.

[14]  M. Humbert,et al.  The molecular targets of approved treatments for pulmonary arterial hypertension , 2015, Thorax.

[15]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) , 2015, European Respiratory Journal.

[16]  H. Ghofrani,et al.  Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) , 2014, European Respiratory Journal.

[17]  G. Simonneau,et al.  The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension , 2013, European Respiratory Review.

[18]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[19]  Chen Wang,et al.  Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. , 2013, The New England journal of medicine.

[20]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[21]  M. Humbert,et al.  Pulmonary arterial hypertension: epidemiology and registries. , 2013, Journal of the American College of Cardiology.

[22]  M. Humbert,et al.  Survivor bias and risk assessment , 2012, European Respiratory Journal.

[23]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[24]  M. Humbert,et al.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.

[25]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[26]  M. Gladwin,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[27]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[28]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.